1Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ typel receptor antagonist on electrical and structural remodeling in atrial fibrillation[J]. J Am Coil Cardioh 2003,41(12):2197-2204.
2Madrid AH,Bueno MG,Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study [J].Circulation, 2002,106 (3) : 331-336.
6Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin converting enzyme in human atria during atrial fibrillation[J]. J Am Coil Cardiol, 2000,35 ( 6 ) : 1669-1677.
7Goette A,Arndt M, Rocken C, et al. Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in humans[J].Circulation, 2000,101 (23) : 2678-2681.
1Lee YA, Liang CS, Lee MA, et al. Local stress, not systemic factors, regulate gene expression of the cardiac renninangiotensin system in vivo: a comprehensive study of all components in the dog. Proc Natl Acad Sci USA, 1996, 93:11035-11040.
2Ikram H. The rennin-angiotensin-aldosterone system and cardiac ischemia. Heart, 1996, 76 (supply3) :560-567.
3Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol, 2003, 41:2197-2204.
4Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.Circulation, 1999, 100:376-380.
5Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation, 2002, 106:331-336.
6Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol,2000,35:1669-1677.
7Everett TH, Li H, Mangrum JM, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation, 2000,102:1454-1460.
8Pfeffer MA. Enhancing cardiac protection after myocardial infarction rationale for newer clinical trials of angiotensin Ⅱ receptor blockers. Am Heart J,2000,139: s23-s28.
9Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in humans. Circulation, 2000, 101:2678-2681.
10Li D, Shinagawa K, Pang L, et al. Effects of angiotensinconverting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation, 2001,104:2608-2614.
